Peking University Cancer Hospital & Institute
Beijing, Haidian District, 100142, China
Location status: Recruiting
Location contact
Lin Wang, M.D.
CONTACT
Lin Wang, M.D.
PRINCIPAL_INVESTIGATOR
Xiaokang Lei, M.D.
CONTACT
NCT Number: NCT06209099
The goal of this clinical trial is to test the safety and efficacy of local excision (LE) or non-operative management (NOM) in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX. The main questions it aims to answer are:
1. What is the organ-preservation rate (OPR) after in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX? 2. Is LE or NOM safe and effective in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX? Participants will receive radical surgery, LE, or NOM based on the response of neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation CapeOX in patients with MRI defined low-risk rectal cancer.
Interested in participating?
Request Info18 year–85 year
All sexes
Interventional
Not applicable
Beijing, Haidian District, 100142, China
Location status: Recruiting
Lin Wang, M.D.
CONTACT
Lin Wang, M.D.
PRINCIPAL_INVESTIGATOR
Xiaokang Lei, M.D.
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
Time frame: Three years
The rate of organ preservation will be defined as the percentage of patients who achieve cCR or near-cCR after neoadjuvant treatment followed by local excision or non-operative management (NOM). The time of organ preservation will be measured from the initiation of treatment.
Time frame: Three years
NR-DFS will be defined as the length of time after treatment until death (any cause), tumor relapse including local pelvic recurrence following TME or local resection and any distant metastasis during or after treatment. Surgical salvageable local regrowth occurs in non-operative management will not be defined as tumor relapse.
Time frame: Three years
Stoma-free survival will be defined as the length of time in which patients live with a temporary or permanent stoma and be measured from the initiation of treatment. Events for stoma-free survival are temporary or permanent stoma or death (any cause). Temporary ileostomy-free survival or colostomy-free survival will also be calculated.
Time frame: Three years
Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
Contact information is provided by the study sponsor or research team.
Lin Wang, M.D.
CONTACT
Xiaokang Lei, M.D.
CONTACT
Peking University Cancer Hospital & Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04098471
Colorectal Neoplasms, Digestive System Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07104604
Colorectal Neoplasms, Digestive System Diseases
Shantou, Guangdong, China
View Trial DetailsNCT06340646
Adenocarcinoma, Blood Protein Disorders
St Louis, Missouri, United States
View Trial DetailsNCT06205485
Colorectal Neoplasms, Digestive System Diseases
Phoenix, Arizona, United States
View Trial Details